Kinesin inhibitors as cancer therapeutics

US8664256B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Tinya Abrams · Richmond, US
• Paul A. Barsanti · Emeryville, US
• David Duhl · Newington, US
• Michel Faure · Oakland, US
• Paul A. Renhowe · Danville, US
• Annette Walter · Mill Valley, US

Key dates

• Filing date: Jul 11, 2012
• Grant date: Mar 4, 2014
• Expiry date: Jul 11, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D233/61
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of drug resistant tumors, such as solid tumors that express elevated levels of P-glycoprotein.